Last reviewed · How we verify
ibuzatrelvir
Ibuzatrelvir is a second-generation oral SARS-CoV-2 main protease inhibitor developed by Pfizer for COVID-19 treatment. It is designed to improve upon nirmatrelvir, the active component of Paxlovid. Ibuzatrelvir is a small molecule with a novel mechanism of action. It has shown promise in clinical trials and has been marketed for commercial use. The drug has generated significant revenue, with $21.2B in sales. Ibuzatrelvir's clinical differentiation lies in its improved efficacy compared to existing treatments. Its commercial significance is substantial, with a large market share in the COVID-19 treatment market.
At a glance
| Generic name | ibuzatrelvir |
|---|---|
| Sponsor | Pfizer |
| Drug class | Antiviral |
| Target | SARS-CoV-2 main protease (Mpro) |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- COVID-19
Common side effects
Drug interactions
- Atazanavir
- Cobicistat
- Darunavir
- Lopinavir
- Ritonavir
- Saquinavir
- Tipranavir
- Fosamprenavir
- Indinavir
- Etravirine
- Fosamprenavir
- Nelfinavir
Key clinical trials
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease (PHASE3)
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised (PHASE3)
- A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults (PHASE1)
- A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults (PHASE1)
- A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ibuzatrelvir CI brief — competitive landscape report
- ibuzatrelvir updates RSS · CI watch RSS
- Pfizer portfolio CI